Tamoxifen case on Endometrial Adenocarcinoma (MCQ)


A 46-year-old female presents with irregular menstrual bleeding that has persisted recently. Her medical history consists of
2 full-term pregnancies and
invasive ductal carcinoma of the breast that was successfully treated with tamoxifen. 
She was recently diagnosed with type 1 endometrioid adenocarcinoma.

Which of the following factors most likely increased this patient's risk for developing this cancer?
  • A. Family history of breast cancer.
  • B. Oral contraceptive use.
  • C. Her pre-premenopausal stat.
  • D. multiple pregnancies.
  • E. Tamoxifen used to treat breast cancer.

Check your answer ...



Tamoxifen has a stimulatory effect on the endometrium, leading to an increased risk of developing
endometrial hyperplasia and eventually endometrial carcinoma.

Tamoxifen is a selective estrogen receptor modulator (SERM) used in the treatment of estrogen
receptor positive breast cancer.

Tamoxifen is an estrogen agonist in endometrial tissue but an estrogen antagonist in the
breast. Therefore, while tamoxifen antagonist activity in the breast makes it an effective agent in the
treatment breast cancer, its agonist effect in the endometrial tissue of the uterus can lead to
excessive endometrial stimulation.

A benefit of the estrogenic activity of tamoxifen in bone is an increase in bone mineral density, making
tamoxifen a useful agent in the treatment of osteoporosis.


Pharmacist interested in improving the health outcome for every single case he meets.